Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study
about
A Comprehensive Review of Clinical Trials on EGFR Inhibitors Such as Cetuximab and Panitumumab as Monotherapy and in Combination for Treatment of Metastatic Colorectal CancerEffectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysisPutative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patientsBiological agents in gastrointestinal cancers: adverse effects and their management.Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer.Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342Synchronous oesophagectomy and hepatic resection for metastatic oesophageal cancer: report of a caseNew trends in epidermal growth factor receptor-directed monoclonal antibodies.EGFR(S) inhibitors in the treatment of gastro-intestinal cancers: what's new?Role of cetuximab in first-line treatment of metastatic colorectal cancerBiologic modulation of chemotherapy in patients with hepatic colorectal metastases: the role of anti-VEGF and anti-EGFR antibodies.Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: development of cetuximab and panitumumab.Chinese guidelines for the diagnosis and comprehensive treatment of hepatic metastasis of colorectal cancer.Cetuximab: a guide to its use in combination with FOLFIRI in the first-line treatment of metastatic colorectal cancer in the USA.Impact of cetuximab in current treatment of metastatic colorectal cancer.The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors.Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study.First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer.DeCoST: A New Approach in Drug Repurposing From Control System Theory.
P2860
Q26775711-AEE2B072-5A3B-4421-8112-93BBA2882003Q26777704-87349BDB-8E31-41D1-8172-2ACC4CE8C074Q33621891-C746F05A-AFA6-47EA-9440-C5E9BDC53B8DQ33895581-3ABD2846-D255-4DF1-A774-BB6EF77CDA5BQ33983663-43277EAC-B74A-4670-BC23-DDDA648EC83BQ34488787-DD70DBD6-3750-4985-887A-587CC7F883F5Q34541316-B8AC3EB3-4260-48DA-B6EC-CE51932C62FAQ34621577-B18066EC-5320-4CF3-985E-6B567359620BQ37561771-025D269C-21C3-44F9-A036-11EF9C9C73EAQ37708010-4F6E8A48-18ED-4B77-BB3C-4BF4C8A3AC18Q37821843-8CF6F1AA-8660-4A72-9AEC-6B84DDC26EEFQ37856053-D582A248-0BBB-49E2-9A31-4A68FB69179CQ37907117-975EB6EF-A362-4438-94AD-BC3B3D54CA69Q38051281-8D84880C-C162-45EF-ACB0-D643C8CB4FEBQ38183447-98BED8F9-C11C-4809-A62E-957270D31D20Q38481038-40C05DE2-388E-47D3-BA12-FC75A2242F2FQ39925893-1478738B-3FD4-4D44-A09B-49A9EF617BF4Q46972709-FFDB99FD-F8FD-4D02-8D24-B083C3375DF3Q55260753-642B636F-5DB3-4FB5-AE4B-32556AF5E813
P2860
Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cetuximab in combination with ...... ntre two-part phase I/II study
@en
Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid
@nl
type
label
Cetuximab in combination with ...... ntre two-part phase I/II study
@en
Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid
@nl
prefLabel
Cetuximab in combination with ...... ntre two-part phase I/II study
@en
Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid
@nl
P2093
P2860
P921
P356
P1433
P1476
Cetuximab in combination with ...... ntre two-part phase I/II study
@en
P2093
Anja-Helena Loos
Catherine Brezault
Fares Husseini
Jean-Luc Raoul
Jean-Luc Van Laethem
Johannes Nippgen
Laurent Cals
Philippe Rougier
P2860
P2888
P356
10.1186/1471-2407-9-112
P407
P50
P577
2009-04-14T00:00:00Z
P5875
P6179
1027981860